Cargando…

Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem

Long non-coding RNAs (lncRNAs) are an emerging group of RNAs with a crucial role in cancer pathogenesis. In gastrointestinal cancers, TP53 target 1 (TP53TG1) is an epigenetically regulated lncRNA that represents a promising therapeutic target due to its tumor suppressor properties regulating the p53...

Descripción completa

Detalles Bibliográficos
Autores principales: Masoumi, Farimah, Saraiva, Sofia M., Bouzo, Belén L., López-López, Rafael, Esteller, Manel, Díaz-Lagares, Ángel, de la Fuente, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470159/
https://www.ncbi.nlm.nih.gov/pubmed/34575588
http://dx.doi.org/10.3390/pharmaceutics13091507
_version_ 1784574127202369536
author Masoumi, Farimah
Saraiva, Sofia M.
Bouzo, Belén L.
López-López, Rafael
Esteller, Manel
Díaz-Lagares, Ángel
de la Fuente, María
author_facet Masoumi, Farimah
Saraiva, Sofia M.
Bouzo, Belén L.
López-López, Rafael
Esteller, Manel
Díaz-Lagares, Ángel
de la Fuente, María
author_sort Masoumi, Farimah
collection PubMed
description Long non-coding RNAs (lncRNAs) are an emerging group of RNAs with a crucial role in cancer pathogenesis. In gastrointestinal cancers, TP53 target 1 (TP53TG1) is an epigenetically regulated lncRNA that represents a promising therapeutic target due to its tumor suppressor properties regulating the p53-mediated DNA damage and the intracellular localization of the oncogenic YBX1 protein. However, to translate this finding into the clinic as a gene therapy, it is important to develop effective carriers able to deliver exogenous lncRNAs to the targeted cancer cells. Here, we propose the use of biocompatible sphingomyelin nanosystems comprising DOTAP (DSNs) to carry and deliver a plasmid vector encoding for TP53TG1 (pc(TP53TG1)-DSNs) to a colorectal cancer cell line (HCT-116). DSNs presented a high association capacity and convenient physicochemical properties. In addition, pc(TP53TG1)-DSNs showed anti-tumor activities in vitro, specifically a decrease in the proliferation rate, a diminished colony-forming capacity, and hampered migration and invasiveness of the treated cancer cells. Consequently, the proposed strategy displays a high potential as a therapeutic approach for colorectal cancer.
format Online
Article
Text
id pubmed-8470159
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84701592021-09-27 Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem Masoumi, Farimah Saraiva, Sofia M. Bouzo, Belén L. López-López, Rafael Esteller, Manel Díaz-Lagares, Ángel de la Fuente, María Pharmaceutics Article Long non-coding RNAs (lncRNAs) are an emerging group of RNAs with a crucial role in cancer pathogenesis. In gastrointestinal cancers, TP53 target 1 (TP53TG1) is an epigenetically regulated lncRNA that represents a promising therapeutic target due to its tumor suppressor properties regulating the p53-mediated DNA damage and the intracellular localization of the oncogenic YBX1 protein. However, to translate this finding into the clinic as a gene therapy, it is important to develop effective carriers able to deliver exogenous lncRNAs to the targeted cancer cells. Here, we propose the use of biocompatible sphingomyelin nanosystems comprising DOTAP (DSNs) to carry and deliver a plasmid vector encoding for TP53TG1 (pc(TP53TG1)-DSNs) to a colorectal cancer cell line (HCT-116). DSNs presented a high association capacity and convenient physicochemical properties. In addition, pc(TP53TG1)-DSNs showed anti-tumor activities in vitro, specifically a decrease in the proliferation rate, a diminished colony-forming capacity, and hampered migration and invasiveness of the treated cancer cells. Consequently, the proposed strategy displays a high potential as a therapeutic approach for colorectal cancer. MDPI 2021-09-18 /pmc/articles/PMC8470159/ /pubmed/34575588 http://dx.doi.org/10.3390/pharmaceutics13091507 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Masoumi, Farimah
Saraiva, Sofia M.
Bouzo, Belén L.
López-López, Rafael
Esteller, Manel
Díaz-Lagares, Ángel
de la Fuente, María
Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem
title Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem
title_full Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem
title_fullStr Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem
title_full_unstemmed Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem
title_short Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem
title_sort modulation of colorectal tumor behavior via lncrna tp53tg1-lipidic nanosystem
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470159/
https://www.ncbi.nlm.nih.gov/pubmed/34575588
http://dx.doi.org/10.3390/pharmaceutics13091507
work_keys_str_mv AT masoumifarimah modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem
AT saraivasofiam modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem
AT bouzobelenl modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem
AT lopezlopezrafael modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem
AT estellermanel modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem
AT diazlagaresangel modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem
AT delafuentemaria modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem